X

AML

AML

The Importance of Induction Chemotherapy in the AML Treatment

Dr Jeffrey Lancet gives an overview of the importance of induction chemotherapy in the treatment of acute myeloid leukemia.

09/08/2021
The Role of MRD in AML

Dr Jacqueline Cloos talks on the role of measurable residual disease as a prognostic factor in the management of acute myeloid leukemia.

09/08/2021
How Molecular Testing Has Transformed AML Treatment Options

Dr David Sallman explains how molecular testing has transformed AML care, including a discussion of risk assessment and the role of next-generation sequencing.

09/05/2021

New Approaches for AML Patients Who Are Not Candidates for Intensive Therapy

Dr Stéphane de Botton discusses novel treatment approached for patients with acute myeloid leukemia who are not candidates for intensive therapy.

06/27/2021
Treatment Cessation Using Venetoclax-Based Therapy for Older Patients With AML

Dr Andrew Wei discusses the combination of venetoclax with low-dose therapy as a new standard of care for older patients with AML who have not received prior treatment...

06/28/2021
Impact of Splicing Factor Mutations on AML Treatment

Dr Curtis Lachowiez discusses a recent paper investigating splicing factor mutations in patients with acute myeloid leukemia.

06/07/2021
High Dose Therapy and Autologous Stem Cell Transplantation
red blood cells

Discussion on high dose therapy and autologous stem cell transplantation.

Understanding Risk in AML: How Molecular Testing Affects Treatment Options

How does molecular testing impact AML treatment options? Dr. Pinkal Desai discusses molecular testing and how results may help determine the best treatment path for patients.

11/19/2020
What Are the Goals of AML Treatment?

Dr. Pinkal Desai defines the role of remission and the specific goals of treatment for AML patients.

11/19/2020
An update on the NCRI AML20 trial

Charles Craddock describes the three main questions the trial aims to address, including whether the addition of venetoclax can improve the activity of CPX-351 in adults with AML.

10/21/2020
What is new in targeted therapies for AML?

Dr. Navel Daver discusses the use of single agents, such as the FLT3 inhibitor, gilteritinib, and the IDH1 inhibitor, ivosidenib, as well as the outcomes of more recent combination treatments with

10/19/2020
Choosing an AML Treatment Path: What Should You Consider?

What should be considered when choosing an AML treatment path? Dr. Pinkal Desai explains the factors that are considered to determine the best treatment for an individual patient.

11/19/2020
Is HSCT an option for refractory AML?

During the 3rd Annual Meeting of the IACH, the AML Hub was pleased to speak to Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne University, Paris, FR.

09/30/2020
Challenges in MRD measurement by multiparameter flow cytometry in AML

Professor Jacqueline Cloos, Amsterdam University Medical Center, Amsterdam, NL, presented the topic ‘Challenges in MRD measurement by multiparameter flow cytometry in AML.’

09/11/2020
How should sequential therapy be performed in patients with AML?

During the 46th Annual Meeting of the EBMT, the AML Hub spoke to Rémy Duléry, Hôpital Saint-Antoine, Paris, FR, about sequential therapy in patients with relapsed/refractory AML.

09/02/2020
ASH Clinical Practice Guidelines on Acute Myeloid Leukemia (AML) In Older Adults

 

The ASH Clinical Practice Guidelines for Acute Myeloid Leukemia covers the treatment of acute myeloid leukemia in older adults.

08/06/2020
Treating older patients with AML in 2020: What is new and promising?

During the 25th Congress of the EHA, the AML Hub spoke to Courtney DiNardo, MD Anderson Cancer Center, Houston, US, about the treatment of elderly patients with AML in 2020.

06/22/2020
David Steensma: Examining H3B-8800 for Myeloid Neoplasms

Dr. David Steensma discusses the results and unanswered questions raised by the first-in-human trial of the splicing modulator in patients with AML, CML...

 

12/16/2019
Uma Borate: Evaluating MBG453 in High-Risk MDS and AML

Combining MBG453 with hypomethylating agents was "extremely well tolerated," with no high-grade immune-related toxicities. Dr. Uma Borate discusses the safety and preliminary efficacy data.

12/16/2019

source list reference

rgb(171, 222, 222)
#7d60d9
#2694a4
#32a887
200, 66, 245
#85eb24
rgb(195, 2, 230)
#352625
#4d4537
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
#d2093c
#8e3f1c
#76b6c3
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
#bfcfc8
#c61417
rgb(156, 242, 7)
#67e25b
#efef71
#03cffc
rgb(224, 4, 129)
#42fc9a
rgb(80, 147, 199)
#cc529a
#c59445
#c8cc0c
#bf6be3
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
#a153ac
rgb(5, 235, 235)
#e7f6e3
#6fc969
#9a8c2c
#a9c507
rgb(235, 190, 9)
#2b9ab3
#e61923
rgb(209, 227, 11)
#990677
#4a7bab
200, 66, 245
#89f67c
#49a21d
#2c990a
#d7da81
#f5ce42
rgb(217, 7, 192)
#575662
#a60538
rgb(2, 230, 230)
#49cde9
#c20fce
rgb(80,199,199)
#d95d39
#eb5834